AI trial to tackle breast cancer launched

Nearly 700,000 women across the country will take part in a trial to test how AI tools can be used to catch breast cancer cases earlier, the DHSC has announced.

© National Cancer Institute/Unsplash

© National Cancer Institute/Unsplash

Under the plans, 30 testing sites across the country will be enhanced with the latest digital AI technologies, ready to invite women already booked in for routine screenings on the NHS to take part.

The technology will assist radiologists, screening patients to identify changes in breast tissue that show possible signs of cancer and referred for further investigations if required.

Currently two specialists are needed per mammogram screening, but this technology will enable just one to complete the same mammogram screening process safely and efficiently.

The EDITH trial is backed by £11m of government support via the National Institute for Health and Care Research (NIHR).

Prof Lucy Chappell, chief scientific adviser at the DHSC and chief executive of the NIHR, said: ‘This landmark trial could lead to a significant step forward in the early detection of breast cancer, offering women faster, more accurate diagnoses when it matters most. 

‘It is another example of how NIHR research, shaped and funded by the public, is crucial for rigorously testing world-leading new technologies, such as AI, that can potentially save lives while reducing the burden on the NHS.'

AI power improves cataract detection tool for babies

AI power improves cataract detection tool for babies

By Liz Wells 15 April 2025

A device invented by an Addenbrooke’s Hospital eye surgeon to detect cataracts in babies is set to be further improved.

Charities call for UK Government to support WHO resolution on kidney disease

By Liz Wells 14 April 2025

Kidney charities are calling on the UK Government to support a World Health Organisation (WHO) resolution on kidney disease.

Targeted breast cancer treatment approved for routine NHS use

By Liz Wells 11 April 2025

NICE is recommending capivasertib with fulvestrant to treat women with advanced breast cancer, which means the drug will be funded immediately through the Ca...


Popular articles by Liz Wells